Therefore, we selected non-ESCC cell lines with low SMARCA2 mRNA expression43 and identified four cell lines - HCT 116, SK-CO-1 (both colorectal carcinoma), HuP-T4 (pancreas carcinoma) and OV-90 (ovarian carcinoma) - with low or non-detectable SMARCA2 protein expression suitable for CRISPR-Cas9 depletion studies (Supplementary Fig. S5). This evidence concerns the gene SMARCA2 and ovarian carcinoma.